Ziopharm Drug Candidate Awarded Orphan Drug Status
From Associated Press (September 23, 2010)
NEW YORK -- Ziopharm Oncology Inc. said Thursday that the Food and
Drug Administration has granted orphan drug status to Zinapar, a
potential treatment for some aggressive lymphomas.
Orphan drug status is given to drugs aimed at rare conditions or conditions that have a lack of treatments on the market.
Incentives for such drugs include seven years of market exclusivity following FDA approval, an accelerated review process, a reduction in user fees and tax credits.
Zinapar, or darinaparsin, received the status for the treatment of peripheral T-cell Lymphoma, which represents about 10 percent to 15 percent of the estimated new cases of non-Hodgkin’s lymphoma diagnosed each year in the United States, according to Ziopharm.
Company shares rose 20 cents, or 5 percent, to $4.18 in morning trading.
Posted: September 2010
